A rare case of anti-NMDAR encephalitis in a 30-year-old female who presented with isolated left temporomandibular joint (TMJ) dystonia, jaw tremor, and facial pain as the sole manifestations for seven months, without clinically significant psychiatric, cognitive, or seizure symptoms is reported.
Abstract
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis typically presents with psychiatric symptoms, seizures, and cognitive dysfunction. Movement disorders, when present, usually coexist with these features. We report a rare case of anti-NMDAR encephalitis in a 30-year-old female who presented with isolated left temporomandibular joint (TMJ) dystonia, jaw tremor, and facial pain as the sole manifestations for seven months, without clinically significant psychiatric, cognitive, or seizure symptoms. The patient was repeatedly misdiagnosed with TMJ disorder and muscular dysfunction before anti-NMDAR IgG antibodies were detected by cell-based assay (CBA) in serum (1:32) and cerebrospinal fluid (CSF, 1:1). First-line immunotherapy with intravenous immunoglobulin (IVIG) achieved remission. However, she relapsed five months later following COVID-19 infection, with antibody titers rising to 1:100 in both serum and CSF. High-dose corticosteroid pulse therapy and maintenance mycophenolate mofetil were administered, achieving sustained clinical improvement over four years of follow-up, although mild residual focal dystonia persisted. Whole-exome sequencing and hereditary ataxia screening excluded genetic causes. This case broadens the clinical spectrum of anti-NMDAR encephalitis and underscores the importance of early antibody testing in young patients with treatment-refractory orofacial movement disorders.
During disease progression, innovative sequential therapy with efgartigimod, an FcRn antagonist, was followed by the anti-CD20 monoclonal antibody rituximab (RTX) to reduce the risk of profound B-cell depletion, thereby demonstrating synergistic efficacy.
Jun-Tong Liu, Wen-Ping Zhu, Lan Gao et al.· Frontiers in Immunology· 1 citation
Anti-N-methyl-D-aspartate receptor encephalitis frequently presents with isolated psychiatric symptoms indistinguishable from primary psychosis, delaying diagnosis. The authors have described a previously healthy 35-year-old woman admitted with abrupt first-episode psychosis, who (within 48 hours and without seizures,...
M. Basta, C. Bikis, A. Miliaras et al.· The Permanente Journal· 0 citations
Progressive encephalomyelitis with rigidity and myoclonus (PERM) represents the most severe subtype of stiff-person spectrum disorders and is exceedingly rare in children. We report a 14-year-old female patient who presented with chronic joint pain and axial rigidity as the initial manifestations, with a disease course...
Xiao-Xue Zou, Lian Meng, Jin-Yu Huang et al.· Frontiers in Immunology· 0 citations
Findings support the possibility that anti-mGluR1 encephalitis may, in rare instances, present with predominant brainstem involvement and testing for anti-mGluR1 antibodies may be considered in patients with otherwise unexplained subacute inflammatory brainstem syndromes.
Rationale: Autoimmune encephalitis in children often presents with neuropsychiatric symptoms and seizures and may progress to secondary epilepsy with prolonged functional impairment. Immunotherapy is the principal disease-modifying treatment, whereas comprehensive nursing care supports safety, complication prevention,...
Background Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the commonest form of autoimmune encephalitis of childhood. However, little information is captured with formal neuropsychological testing. When the pre-illness history is incomplete, it is also hard to judge how much of the residual picture reflects...
Felipe Dalvi-Garcia, Iolanda de Salles Fonseca Carvalho, Julia Valeriano de Almeida et al.· Brain, Behavior, & Immunity...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.